Phase 2Completed
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty
A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
- Sponsor
- Longeveron Inc. (Industry)
- Enrolment
- 150 enrolled
- Conditions
- Aging Frailty
- Interventions
- Longeveron Mesenchymal Stem Cells (LMSCs); Placebo
- Ages
- older adults
- Registry
- NCT03169231
From the registry
This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
Primary outcomes
- Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo